213 related articles for article (PubMed ID: 35413618)
21. Natural Products and Their Derivatives as Inhibitors of the DNA Repair Enzyme Tyrosyl-DNA Phosphodiesterase 1.
Zakharenko AL; Luzina OA; Chepanova AA; Dyrkheeva NS; Salakhutdinov NF; Lavrik OI
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982848
[TBL] [Abstract][Full Text] [Related]
22. Secondary metabolites from Isodon ternifolius (D. Don) Kudo and their anticancer activity as DNA topoisomerase IB and Tyrosyl-DNA phosphodiesterase 1 inhibitors.
Zhang HL; Zhang Y; Yan XL; Xiao LG; Hu DX; Yu Q; An LK
Bioorg Med Chem; 2020 Jun; 28(11):115527. PubMed ID: 32345458
[TBL] [Abstract][Full Text] [Related]
23. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
[TBL] [Abstract][Full Text] [Related]
24. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
25. Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.
Das SK; Ghosh A; Paul Chowdhuri S; Halder N; Rehman I; Sengupta S; Sahoo KC; Rath H; Das BB
J Med Chem; 2018 Feb; 61(3):804-817. PubMed ID: 29290109
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase I poisons and suppressors as anticancer drugs.
Bailly C
Curr Med Chem; 2000 Jan; 7(1):39-58. PubMed ID: 10637356
[TBL] [Abstract][Full Text] [Related]
27. Tipin functions in the protection against topoisomerase I inhibitor.
Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
[TBL] [Abstract][Full Text] [Related]
28. Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity.
Zakharenko A; Dyrkheeva N; Lavrik O
Med Res Rev; 2019 Jul; 39(4):1427-1441. PubMed ID: 31004352
[TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
[TBL] [Abstract][Full Text] [Related]
31. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
32. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
Adachi N; So S; Koyama H
J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
[TBL] [Abstract][Full Text] [Related]
33. Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies.
Zeng H; Zhang S; Nie H; Li J; Yang J; Zhuang Y; Huang Y; Zeng M
Bioorg Chem; 2024 Jun; 147():107412. PubMed ID: 38696845
[TBL] [Abstract][Full Text] [Related]
34. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
35. A Yeast-Based Screening System for Differential Identification of Poisons and Suppressors of Human Topoisomerase I.
Seddek A; Madeira C; Annamalai T; Mederos C; Tiwari PB; Welch AZ; Tse-Dinh YC
Front Biosci (Landmark Ed); 2022 Mar; 27(3):93. PubMed ID: 35345325
[TBL] [Abstract][Full Text] [Related]
36. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase I inhibitors: camptothecins and beyond.
Pommier Y
Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
[TBL] [Abstract][Full Text] [Related]
38. Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
Kundu B; Das SK; Paul Chowdhuri S; Pal S; Sarkar D; Ghosh A; Mukherjee A; Bhattacharya D; Das BB; Talukdar A
J Med Chem; 2019 Apr; 62(7):3428-3446. PubMed ID: 30897325
[TBL] [Abstract][Full Text] [Related]
39. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
40. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
